Pharmaceutical Industry Shares new Policy Recommendations to Address the Growing Burden of Mental and Neurological Disorders
GENEVA, October 10, 2012 /PRNewswire/ –
- Publication contains recommendations for governments and other stakeholders to address MNDs - Research in this disease area is complex, time-consuming, and needs to be incentivized - Launch coincides with World Mental Health Day to raise awareness on the burden of mental and neurological disorders on society
Today the International Federation of Pharmaceutical Manufacturers and Associations
(IFPMA) released MNDs: Innovative therapies, innovative collaborations, a publication
outlining policy recommendations for further research and to address the growing burden of
mental and neurological disorders on populations worldwide. In releasing this publication,
industry encourages governments and other stakeholders to consider the social and economic
impact of these disorders beyond the health sector.
Many mental and neurological disorders are not very well understood, which stifles
diagnosis, and poses a challenge to innovating breakthrough medicines. This presents an
important and urgent priority for the global health community, including the
research-based pharmaceutical industry, governments, the World Health Organization (WHO),
patient groups, and other stakeholders.
“Our companies have made substantial investments and progress towards deepening the
understanding of how the brain works,” said Eduardo Pisani, IFPMA Director General. “Many
research challenges remain, and more innovation is clearly needed both in and beyond the
labs to address this growing health priority.”
The release of this publication coincides with World Mental Health Day on 10 October
2012. This year’s theme is of “Depression: A Global Crisis.” According to the WHO, mental
and neurological disorders are responsible for 13% of the global disease burden Depression
alone affects more than 350 million people and will become the largest cause of disease in
the world by 2030. MNDs: Innovative Therapies, Innovative Collaborations explains
industry’s current efforts and highlights collaborative ways to go forward.
The full report can be accessed here:
About the IFPMA:
IFPMA represents the research-based pharmaceutical companies and associations across
the globe. The research-based pharmaceutical industry’s 1.3 million employees research,
develop and provide medicines and vaccines that improve the life of patients worldwide.
Based in Geneva, IFPMA has official relations with the United Nations and contributes
industry expertise to help the global health community find solutions that improve global